Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2009

01-03-2009 | Original Article

Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus

Authors: Márcio Veronesi Fukuda, Simone Chinwa Lo, Cláudia Salvini de Almeida, Samuel Katsuyuki Shinjo

Published in: Clinical Rheumatology | Issue 3/2009

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with various clinical and serological manifestations. Previous studies have shown the association of SLE and anti-Ro antibody with a series of clinical manifestations. We investigated this association in Brazilian patients with SLE. Five hundred and nine consecutive patients who fulfilled the revised American College of Rheumatology criteria for the SLE were enrolled in the study from June to December 2007. All patients were from our Service of Rheumatology, School of Medicine, University of São Paulo, Brazil. Frequencies of a series of laboratorial and clinical manifestations were calculated. Anti-Ro antibody was associated to anti-La antibody, female, and cutaneous vasculitis. In multivariate analysis, patients with anti-Ro antibody has 1.63 (95% CI 1.07–2.50) more risk to develop cutaneous vasculitis than patients without this antibody. Our data have demonstrated that anti-Ro antibody is an independent useful serologic marker for cutaneous vasculitis.
Literature
1.
Sibilia J (1998) Ro (SS-A) and anti-Ro (SS-A): an update. Rev Rhum Engl Ed 65:45–57PubMed
2.
Harley JB, Scofield RH, Reichlin M (1992) Anti-Ro in Sjögren’s syndrome and systemic lupus erythematosus. Rheum Dis Clin North Am 18:337–358PubMed
3.
Penner E, Reichlin M (1982) Primary biliary cirrhosis associated with Sjögren’s syndrome: evidence for circulating and tissue-deposited Ro/anti-Ro immune complexes. Arthritis Rheum 25:1250–1253PubMedCrossRef
4.
Cavazzana I, Franceschini F, Quinzanini M, Manera C, Del Papa N, Maglione W, Comina D, Radice A, Sinico RA, Cattaneo R (2006) Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 24:59–64PubMed
5.
Wolin SL, Reinisch KM (2006) The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments or structure. Autoimmun Rev 5:367–372PubMedCrossRef
6.
Provost TT, Levin LS, Watson RM, Mayo M, Ratrie H 3rd (1991) Detection of anti Ro(SSA) antibodies by gel double diffusion and a sandwich ELISA in systemic and subacute cutaneous lupus erythematosus and Sjogren’s syndrome. J Autoimmun 4:87–96PubMedCrossRef
7.
Clark G, Reichlin M, Tomasi TB (1969) Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus. J Immunol 102:117–122PubMed
8.
Maddison PJ, Mogavero M, Provost TT, Reichlin M (1976) The clinical significance of autoantibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 6:189–195
9.
Synkowski DR, Reichlin M, Provost TT (1982) Serum autoantibodies in systemic lupus erythematosus and correlation with cutaneous features. J Rheumatol 9:380–385PubMed
10.
Hochberg MC, Boyd RE, Aheran JM, Arnett FC, Bias WB, Provost TT, Stevens MB (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markerjs in 150 patients with emphasis on demographic subsets. Medicine 64:285–295PubMedCrossRef
11.
Mond CB, Peterson MG, Rothfield NF (1989) Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 32:202–204PubMedCrossRef
12.
Sutej PG, Gear AJ, Morrison RC, Tikly M, de Beer M, Dos Santos L, Sher R (1989) Photosensitivity and anti-Ro (SS-A) antibodies in black patients with systemic lupus erythematosus (SLE). Br J Rheumatol 28:321–324PubMedCrossRef
13.
Kurien BT, Newland J, Paczkowski C, Moore KL, Scofield RH (2000) Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen. Clin Exp Immunol 120:209–217PubMedCrossRef
14.
Vilá LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vilá S (2006) Clinical and prognostic value of autoantibodies in Puerto Ricans with systemic lupus erythematosus. Lupus 15:892–898PubMedCrossRef
15.
Costedoat-Chalumeau N, Georgin-Lavialle S, Amoura Z, Piette JC (2005) Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus 14:660–664PubMedCrossRef
16.
Clancy RM, Neufing PJ, Zheng P, O’Mahony M, Nimmerjahn F, Gordon TP, Buyon JP (2006) Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and –SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 116:2413–2422PubMed
17.
La zzerini PE, Capecchi PL, Guideri F, Acampa M, Galeazzi M, Laghi-Pasini F (2006) Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev 5:306–313PubMedCrossRef
18.
Shahin AA, Shahin HA, Hamid MA, Amin MA (2004) Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SS-A and anti-La/SS-B antibody levels. Mod Rheumatol 14:117–122PubMedCrossRef
19.
Oshiro AC, Derbes SJ, Stopa AR, Gedalia A (1997) Anti-Ro/SS-A and anti-La/SS-B antibodies associated with cardiac involvement in childhood systemic lupus erythematosus. Ann Rheum Dis 56:i272–i274CrossRef
20.
Alexander EL, Arnett FC, Provost TT, Stevens MB (1983) Sjögren’s syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 98:155–159PubMed
21.
Moutsopoulos HM, Zerva LV (1990) Anti-Ro (SSA)/La (SSB) antibodies and Sjögren’s syndrome. Clin Rheumatol 9(1 Suppl 1):123–130PubMedCrossRef
22.
Alexander EL, Provost TT (1983) Cutaneous manifestations of primary Sjögren’s syndrome: a refletion of vasculitis and association with anti-Ro (SSA) antibodies. J Invest Dermatol 80:386–391PubMedCrossRef
23.
Alexander EL, Provost TT (1987) Sjögren’s syndrome. Association of cutaneous vasculitis with central nervous system disease. Arch Dermatol 123:801–810PubMedCrossRef
24.
Alexander EL, Hirsch TJ, Arnett FC, Provost TT, Stevens MB (1982) Ro (SSA) and La (SSB) antibodies in the clinical spectrum of Sjögren’s syndrome. J Rheumatol 9:239–246PubMed
25.
Cho CS, Park SH, Min JK, Lee SH, Kim HY (1997) Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med 12:176–181PubMed
26.
Boire G, Ménard HA (1988) Clinical significance of anti-Ro (SSA) antibody in rheumatoid arthritis. J Rheumatol 15:391–394PubMed
27.
Magro CM, Crowson AN (2003) The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol 30:1–10PubMedCrossRef
28.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef
29.
McCauliffe DP (1997) Cutaneous diseases in adults associated with Anti-Ro/SS-A autoantibody production. Lupus 6:158–166PubMedCrossRef
30.
Dubois EL, Tuffanelli DL (1964) Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 190:104–111PubMed
31.
Harvey AM, Shulman LE, Tumulty PA, Conley CL, Schoenrich EH (1954) Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33:291–437CrossRef
32.
Yell JA, Mbuagbaw J, Burge SM (1996) Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 135:355–362PubMedCrossRef
33.
Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GR (1978) Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 37:121–128PubMedCrossRef
34.
Bouaziz JD, Barete S, Le Pelletier F, Amoura Z, Piette JC, Francès C (2007) Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. Lupus 16:163–167PubMed
35.
Watson R (1989) Cutaneous lesions in systemic lupus erythematosus. Med Clin North Am 73:1091–1111PubMed
36.
Drenkard C, Villa AR, Reyes E, Abello M, Alarcón-Segovia D (1997) Vasculitis in systemic lupus erythematosus. Lupus 6:235–242PubMedCrossRef
37.
Provost TT, Watson R, Simmons-O’Brien E (1996) Anti-Ro (SS-A) antibody positive Sjögren’s/lupus erythematosus overlap syndrome. Lupus 6:105–111CrossRef
Metadata
Title
Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus
Authors
Márcio Veronesi Fukuda
Simone Chinwa Lo
Cláudia Salvini de Almeida
Samuel Katsuyuki Shinjo
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1043-5

Other articles of this Issue 3/2009

Clinical Rheumatology 3/2009 Go to the issue

Brief Report

Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes—an Indian perspective

Case Report

An unusual case of testicular pain

Letter to the Editor

Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations

Case Report

Preeclampsia, dilated cardiomyopathy and renal failure as the first manifestation of systemic lupus erythematosus: a case report

Brief Report

Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model

Case Report

Necrotising scleritis and connective tissue disease—three cases and a review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits